Allergan Extends Offer for Inamed

Botox maker Allergan Inc. said it was extending its $3.2-billion offer to buy breast implant maker Inamed Corp. because it had yet to get antitrust clearance from regulators.

The offer is now set to expire at 8 p.m. on Feb. 7; it had been set to expire today.

Irvine-based Allergan and Santa Barbara-based Inamed said they were working with the Federal Trade Commission to complete the sale of Inamed’s license for Reloxin, a botulism toxin product.